Xcorporeal (Xcorporeal) Change In Working Capital : $-0.61 Mil (TTM As of Sep. 2009)

View and export this data going back to . Start your Free Trial

What is Xcorporeal Change In Working Capital?

Xcorporeal's change in working capital for the quarter that ended in Sep. 2009 was $0.61 Mil.

Xcorporeal's change in working capital for the fiscal year that ended in Dec. 2008 was $2.97 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Xcorporeal Change In Working Capital Historical Data

The historical data trend for Xcorporeal's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal Change In Working Capital Chart

Xcorporeal Annual Data

Trend

Feb99

Feb00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Change In Working Capital

Get a 7-Day Free Trial

-0.08

0.19

2.02

-0.46

2.97

Xcorporeal Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
Change In Working Capital	Get a 7-Day Free Trial															1.45	-0.04	-0.68	-0.49	0.61

Xcorporeal Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.61 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Xcorporeal Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Xcorporeal's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Xcorporeal (Xcorporeal) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Empire Drive, Lake Forest, CA, USA, 92630

Website

Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.

Executives

Kelly J. Mccrann	director, officer: Chairman and CEO	11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger	officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins	director	C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc	10 percent owner	135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer	director, 10 percent owner, officer: Executive Chairman	11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf	director	981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen	director	22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte	10 percent owner	C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122